Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Cash Flow (2016 - 2025)

Ligand Pharmaceuticals' Net Cash Flow history spans 16 years, with the latest figure at $36.1 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 253.08% year-over-year to $36.1 million; the TTM value through Dec 2025 reached $71.4 million, up 41.26%, while the annual FY2025 figure was $100.3 million, 98.44% up from the prior year.
  • Net Cash Flow for Q4 2025 was $36.1 million at Ligand Pharmaceuticals, down from $56.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $56.2 million in Q3 2025 and bottomed at -$60.3 million in Q2 2023.
  • The 5-year median for Net Cash Flow is $129500.0 (2021), against an average of $4.8 million.
  • The largest annual shift saw Net Cash Flow skyrocketed 1146.58% in 2022 before it crashed 637.71% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$3.9 million in 2021, then surged by 1146.58% to $40.9 million in 2022, then plummeted by 92.43% to $3.1 million in 2023, then soared by 230.62% to $10.2 million in 2024, then soared by 253.08% to $36.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Net Cash Flow are $36.1 million (Q4 2025), $56.2 million (Q3 2025), and $4.3 million (Q2 2025).